Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Aggressive lymphomas]

C Gisselbrecht1

  • 1Institut d'hématologie, hôpital Saint-Louis, Paris.

La Revue Du Praticien
|September 1, 1993
PubMed
Summary
This summary is machine-generated.

Aggressive lymphomas, characterized by intermediate severity and high malignancy, are treatable with modern therapies. Treatment strategies are tailored based on prognostic factors to maximize cure rates and long-term survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.

Bone marrow transplantation·2016
Same author

Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.

Bone marrow transplantation·2015
Same author

Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same author

Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria.

Annals of oncology : official journal of the European Society for Medical Oncology·2008
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Clinical Medicine

Context:

  • Aggressive lymphomas encompass a heterogeneous group of intermediate severity and high malignancy lymphomas.
  • Current classifications recognize the need for tailored therapeutic approaches based on prognostic factors.

Purpose:

  • To outline the current therapeutic strategies for aggressive lymphomas.
  • To identify the need for novel treatments in cases with poor prognostic factors.

Summary:

  • Curative treatment for aggressive lymphomas is achievable in 80-90% of cases without adverse prognostic factors, primarily through chemotherapy or chemo-radiotherapy.
  • Treatment intensity is adjusted based on disease severity and prognostic factors, with less toxic options preferred for less severe forms.
  • Intensive treatments, including intensified conventional therapy and hematopoietic stem cell autografts, are being explored for patients with poor prognostic factors, aiming to improve the 40% long-term survival rate.

Related Experiment Videos

Impact:

  • Optimized treatment selection based on prognostic factors can significantly improve cure rates in aggressive lymphomas.
  • The study highlights the need for advanced therapeutic approaches, such as early intensification with stem cell autografts, to enhance long-term survival in high-risk patients.
  • Differentiated treatment protocols are essential for specific subtypes like lymphoblastic and Burkitt lymphomas, particularly when medullary or meningeal tissues are involved.